Abbott's Xience Stent Gains FDA Approval

Abbott’s Xience family of stents has received FDA approval for use in dual anti-platelet therapy blood thinner courses as short as 28 days for high bleeding risk patients.

The Xience stents previously received the CE mark in Europe for the same indication.

Abbott has also received FDA approval and CE mark certification for its Xience Skypoint stent, which enables physicians to open large clogged vessels through improved stent expansion.